Two-thirds of people feel it is ‘unacceptable’ that life-changing medicines are available to patients in other countries before our own can get them, according to a survey conducted by Ipsos MRBI on behalf of Irish Pharmaceutical Healthcare Association (IPHA), the organisation that represents pharmaceutical innovators in Ireland.
Patients in Ireland are waiting more than twice as long as patients in other western European countries for access to many vital new medicines, figures from the Irish Pharmaceutical Healthcare Association (IPHA) have revealed.
IPHA Chief Executive Oliver O’Connor chaired the recent EFPIA Heads of Association meeting in Vienna, with vice Chair Anders Blanck from Sweden’s LEEM.
The meeting took place in Vienna to support Austrian pharma associations’ work with Austria’s current EU Presidency and to enable associations from smaller central and eastern European countries to attend.
As great uncertainty continues to prevail surrounding the eventual impact of Brexit, the industry is working in the background with relevant public health stakeholders on appropriate preparedness.
Planning is on track for the IPHA Annual Conference and Dinner as delegates register ahead of the November 1 deadline for an event that promises to engage a range of perspectives about the future of Ireland’s bio-economy.
A total of 4,191 individual users have trained on the IPHA Code eLearning site since its inception in February 2016